As SGLT2 inhibitors (SGLT2i) are increasingly utilized for broader indications, encompassing the entire spectrum of ejection fraction, it is imperative to further elucidate their role in heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF). This evidence concerns the gene SLC5A2 and heart failure.